References
- 1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61:37-49.10.1016/S0090-4295(02)02243-4
- 2. MacDiarmid S, Sandage BW, Jr., Malhotra BK. The effects of reformulation: improved therapeutic index. Curr Urol Rep. 2008; 9:465-71.10.1007/s11934-008-0080-618947511
- 3. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10:283-9.10.1007/s00192997000310543335
- 4. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995; 44: 423-33.10.1007/BF017576998564518
- 5. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999; 128:1121-32.10.1038/sj.bjp.0702897157174410578123
- 6. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/ Sumatriptan Migraine Study Group. Cephalalgia. 1999; 19:232-40.10.1046/j.1468-2982.1999.019004232.x10376168
- 7. McNeely W, Goa KL. Diclofenac-potassium in migraine: a review. Drugs. 1999; 57:991-1003.10.2165/00003495-199957060-0001610400409
- 8. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache. 1992; 32:98-100.10.1111/j.1526-4610.1992.hed3202098.x1551795
- 9. Kuznetsova AA, Shakhmatova EI, Prutskova NP, Natochin YV. Possible role of prostaglandins in pathogenesis of nocturnal enuresis in children. Scand J Urol Nephrol. 2000; 34:27-31.10.1080/00365590075001684110757266
- 10. Davenport K, Timoney AG, Keeley FX, Jr. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res. 2007; 35:207-13.10.1007/s00240-007-0100-x17530238
- 11. Chaignat V, Danuser H, Stoffel MH, Z’brun S, Studer UE, Mevissen M. Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol. 2008; 154:1297-307.10.1038/bjp.2008.193
- 12. Badawi JK, Li H, Langbein S, Kwon ST, Kamp S, Bross S. Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle. Eur J Clin Pharmacol. 2006; 62:347-54.10.1007/s00228-006-0100-8
- 13. Roosen A, Wu C, Sui G, Chowdhury RA, Patel PM, Fry CH. Characteristics of spontaneous activity in the bladder trigone. Eur Urol. 2009; 56:346-53.10.1016/j.eururo.2008.06.048
- 14. Batislam E, Nuhoglu B, Peskircioglu L, Emir L, Uygur C, Germiyanoglu C, et al. A prostaglandin synthesis inhibitor, diclofenac sodium in the treatment of primary nocturnal enuresis. Acta Urol Belg. 1995; 63:35-8.
- 15. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009; 63:1177-91.10.1111/j.1742-1241.2009.02078.x
- 16. Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999; 84: 923-47.10.1046/j.1464-410x.1999.00397.x
- 17. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003; 326:841-4.10.1136/bmj.326.7394.841
- 18. Roshani A, Falahatkar S, Khosropanah I, Roshan ZA, Zarkami T, Palizkar M, et al. Assessment of clinical efficacy of intranasal desmopressin spray and diclofenac sodium suppository in treatment of renal colic versus diclofenac sodium alone. Urology. 2010; 75:540-2.10.1016/j.urology.2008.05.053
- 19. Iselin CE, Alm P, Schaad NC, Larsson B, Graber P, Andersson KE. Nitric oxide inhibits contraction of isolated pig ureteral smooth muscle. J Urol. 1996; 155: 763-7.10.1016/S0022-5347(01)66517-0
- 20. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87:760-6.10.1046/j.1464-410x.2001.02228.x11412210
- 21. Stewart W, Herzog R, Wein A. The prevalence and impact of overactive bladder in the U.S.: results from the NOBLE program. Neurourol Urodyn. 2001; 20: 406-8.
- 22. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20:327-3610.1007/s00345-002-0301-412811491